Cargando…

Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer

Fascin-1 (FSCN1) is an actin-bundling protein associated with an invasive and aggressive phenotype of several solid carcinomas, as it is involved in cell cytoskeleton rearrangement and filopodia formation. Adrenocortical carcinoma (ACC) is a rare endocrine malignancy characterized by poor prognosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantini, Giulia, Fei, Laura, Canu, Letizia, De Filpo, Giuseppina, Ercolino, Tonino, Nesi, Gabriella, Mannelli, Massimo, Luconi, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261281/
https://www.ncbi.nlm.nih.gov/pubmed/34248854
http://dx.doi.org/10.3389/fendo.2021.698862
_version_ 1783718982387236864
author Cantini, Giulia
Fei, Laura
Canu, Letizia
De Filpo, Giuseppina
Ercolino, Tonino
Nesi, Gabriella
Mannelli, Massimo
Luconi, Michaela
author_facet Cantini, Giulia
Fei, Laura
Canu, Letizia
De Filpo, Giuseppina
Ercolino, Tonino
Nesi, Gabriella
Mannelli, Massimo
Luconi, Michaela
author_sort Cantini, Giulia
collection PubMed
description Fascin-1 (FSCN1) is an actin-bundling protein associated with an invasive and aggressive phenotype of several solid carcinomas, as it is involved in cell cytoskeleton rearrangement and filopodia formation. Adrenocortical carcinoma (ACC) is a rare endocrine malignancy characterized by poor prognosis, particularly when metastatic at diagnosis. Radical resection is the only therapeutic option for ACC patients in addition to the adjuvant treatment with mitotane. Novel specific biomarkers suggestive of tumor progression to refine diagnosis and prognosis of patients with advanced ACC are urgently needed. ACC intratumoral FSCN1 has previously been suggested as a valid prognostic marker. In the present study, we identified FSCN1 in the bloodstream of a small cohort of ACC patients (n = 27), through a specific ELISA assay for human FSCN1. FSCN1 can be detected in the serum, and its circulating levels were evaluated in pre-surgery samples, which resulted to be significantly higher in ACC patients from stage I/II and stage III/IV compared with nontumoral healthy controls (HC, n = 4, FI: 5.5 ± 0.8, P<0.001, and 8.0 ± 0.5, P < 0.001 for stage I/II and stage III/IV group vs HC, respectively). In particular, FSCN1 levels were significantly higher in advanced stage versus stage I/II (22.8 ± 1.1 vs 15.8 ± 1.8 ng/ml, P < 0.005, respectively). Interestingly, circulating levels of pre-surgical FSCN1 can significantly predict tumor progression/recurrence (Log rank = 0.013), but not the overall survival (Log rank=0.317), in patients stratified in high/low PreS FSCN1. In conclusion, these findings—though very preliminary—suggest that circulating FSCN1 may represent a new minimally-invasive prognostic marker in advanced ACC, in particular when measured before surgery enables histological diagnosis.
format Online
Article
Text
id pubmed-8261281
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82612812021-07-08 Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer Cantini, Giulia Fei, Laura Canu, Letizia De Filpo, Giuseppina Ercolino, Tonino Nesi, Gabriella Mannelli, Massimo Luconi, Michaela Front Endocrinol (Lausanne) Endocrinology Fascin-1 (FSCN1) is an actin-bundling protein associated with an invasive and aggressive phenotype of several solid carcinomas, as it is involved in cell cytoskeleton rearrangement and filopodia formation. Adrenocortical carcinoma (ACC) is a rare endocrine malignancy characterized by poor prognosis, particularly when metastatic at diagnosis. Radical resection is the only therapeutic option for ACC patients in addition to the adjuvant treatment with mitotane. Novel specific biomarkers suggestive of tumor progression to refine diagnosis and prognosis of patients with advanced ACC are urgently needed. ACC intratumoral FSCN1 has previously been suggested as a valid prognostic marker. In the present study, we identified FSCN1 in the bloodstream of a small cohort of ACC patients (n = 27), through a specific ELISA assay for human FSCN1. FSCN1 can be detected in the serum, and its circulating levels were evaluated in pre-surgery samples, which resulted to be significantly higher in ACC patients from stage I/II and stage III/IV compared with nontumoral healthy controls (HC, n = 4, FI: 5.5 ± 0.8, P<0.001, and 8.0 ± 0.5, P < 0.001 for stage I/II and stage III/IV group vs HC, respectively). In particular, FSCN1 levels were significantly higher in advanced stage versus stage I/II (22.8 ± 1.1 vs 15.8 ± 1.8 ng/ml, P < 0.005, respectively). Interestingly, circulating levels of pre-surgical FSCN1 can significantly predict tumor progression/recurrence (Log rank = 0.013), but not the overall survival (Log rank=0.317), in patients stratified in high/low PreS FSCN1. In conclusion, these findings—though very preliminary—suggest that circulating FSCN1 may represent a new minimally-invasive prognostic marker in advanced ACC, in particular when measured before surgery enables histological diagnosis. Frontiers Media S.A. 2021-06-23 /pmc/articles/PMC8261281/ /pubmed/34248854 http://dx.doi.org/10.3389/fendo.2021.698862 Text en Copyright © 2021 Cantini, Fei, Canu, De Filpo, Ercolino, Nesi, Mannelli and Luconi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Cantini, Giulia
Fei, Laura
Canu, Letizia
De Filpo, Giuseppina
Ercolino, Tonino
Nesi, Gabriella
Mannelli, Massimo
Luconi, Michaela
Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer
title Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer
title_full Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer
title_fullStr Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer
title_full_unstemmed Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer
title_short Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer
title_sort circulating fascin 1 as a promising prognostic marker in adrenocortical cancer
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261281/
https://www.ncbi.nlm.nih.gov/pubmed/34248854
http://dx.doi.org/10.3389/fendo.2021.698862
work_keys_str_mv AT cantinigiulia circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT feilaura circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT canuletizia circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT defilpogiuseppina circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT ercolinotonino circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT nesigabriella circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT mannellimassimo circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer
AT luconimichaela circulatingfascin1asapromisingprognosticmarkerinadrenocorticalcancer